TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Nabla Bio Secures $26 Million in Series A Funding and Forms Collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda for Protein Design

Wednesday, May 15, 2024

Nabla Bio, known for its innovative work in generative protein design, has reached a significant milestone by securing a Series A financing round of $26 million. This round was led by Radical Ventures, with continued support from all existing investors. Additionally, strategic collaborations with industry leaders like AstraZeneca, Bristol Myers Squibb Company, and Takeda have been solidified, amounting to over $550 million in upfront and milestone payments, along with royalties.

At the core of Nabla's mission is the development of integrated AI and wet-lab technologies, facilitating atomically precise drug design and high-throughput measurement of drug function. Their initial focus lies on antibodies targeting multipass membrane proteins, notably G protein-coupled receptors (GPCRs), ion channels, and transporters.

According to Surge Biswas, Co-Founder and CEO of Nabla, they are pioneering the creation of highly selective drugs against challenging targets with an unprecedented level of structural precision. This endeavor holds promise for advancing therapeutic solutions for previously hard-to-drug targets.

The traditional drug discovery landscape predominantly revolves around soluble, extracellular targets, leaving multipass membrane proteins largely unexplored due to inherent challenges like membrane integration and limited extracellular availability. Nabla's generative protein design platform aims to address these challenges by enabling the precise design of conformation- and target-selective antibody binders.

Nabla, highlights the transformative potential of their technologies, envisioning a doubling of disease-relevant drug targets pursued by the industry. This untapped opportunity has garnered the attention of leading pharmaceutical companies, resulting in collaborative efforts to unlock therapeutic potential.

The partnerships forged by Nabla not only enhance their drug development pipeline but also offer valuable insights into disease biology and platform refinement. This collaborative approach ensures rapid and sustainable growth for Nabla while significantly offsetting R&D expenses.

Beyond multipass membrane protein targets, Nabla's platform demonstrates versatility in designing novel cytokines, complex multi-domain antibodies, and receptor traps with superior activity and developability compared to existing drugs. These advancements signal a promising transition towards clinical therapies and underscore Nabla's expanding capabilities.

Radical Ventures recognizes the transformative potential of generative AI in deciphering the language of proteins, paralleling its mastery in natural language processing. Nabla's pioneering work in this domain, particularly concerning multipass membrane protein targets, has garnered widespread acclaim and strategic partnerships with major pharmaceutical players.

Founded in 2021, Nabla Bio has rapidly ascended in the biotech landscape, building upon Surge Biswas' pioneering work in protein language models. Backed by esteemed investors and fueled by a world-class team, Nabla is poised to revolutionize antibody therapeutics and redefine the boundaries of drug discovery.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit